Metastasis-Directed Therapy Delivers Clear Progression Benefits in Oligometastatic Prostate Cancer: The WOLVERINE IPD Meta-Analysis
Highlights
The WOLVERINE systematic review and individual patient data (IPD) meta-analysis provides the most robust evidence to date regarding the role of metastasis-directed therapy (MDT) in oligometastatic prostate cancer. The study found that MDT, when added to the standard of care (SOC), significantly improves progression-free survival (PFS) with a hazard ratio of 0.44. Furthermore, the intervention significantly delayed the time to castration resistance, a critical milestone in the natural history of prostate cancer. While a trend toward improved overall survival (OS) was observed, the results did not reach conventional statistical significance, highlighting the need for longer-term follow-up and larger phase 3 trials.
The Oligometastatic Spectrum: From Theory to Practice
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.